Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian

NCT02822157 is registered in ClinicalTrials.gov with Universitaire Ziekenhuizen KU Leuven as lead sponsor.

NCT NCT02822157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02822157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian
Lead sponsor
Universitaire Ziekenhuizen KU Leuven
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2016
Completion date
July 31, 2023
Enrollment
160 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian epithelial cancer